Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

XLO

Xilio Therapeutics Inc

Dec 26 • 01:32PM ET

1.07

Dollar change -0.08
Percentage change -6.95	%

Healthcare • Biotechnology • USA • NASD

Peers: BNTX VRTX MRNA AZN ALXO NBIX ARVN IMVT ADPT FOLD

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.72	Insider Own	57.29%	Shs Outstand	43.96M	Perf Week	23.50%
Market Cap	47.04M	Forward P/E	-	EPS next Y	-0.51	Insider Trans	7.23%	Shs Float	18.77M	Perf Month	21.38%
Income	-62.80M	PEG	-	EPS next Q	-0.22	Inst Own	16.09%	Short Float	0.64%	Perf Quarter	42.30%
Sales	4.62M	P/S	10.18	EPS this Y	58.99%	Inst Trans	3.95%	Short Ratio	0.28	Perf Half Y	13.84%
Book/sh	0.48	P/B	2.24	EPS next Y	55.56%	ROA	-82.36%	Short Interest	0.12M	Perf Year	87.41%
Cash/sh	1.39	P/C	0.77	EPS next 5Y	-	ROE	-170.96%	52W Range	0.50 - 1.93	Perf YTD	94.56%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-44.91%	ROI	-222.41%	52W High	-44.55%	Beta	-0.26
Dividend TTM	-	Quick Ratio	1.67	Sales past 5Y	0.00%	Gross Margin	62.40%	52W Low	113.98%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	1.67	EPS Y/Y TTM	41.89%	Oper. Margin	-1388.44%	RSI (14)	51.92	Volatility	21.97% 12.62%
Employees	73	Debt/Eq	0.40	Sales Y/Y TTM	-	Profit Margin	-1359.37%	Recom	1.33	Target Price	4.50
Option/Short	No / Yes	LT Debt/Eq	0.35	EPS Q/Q	63.70%	Payout	-	Rel Volume	1.28	Prev Close	1.15
Sales Surprise	-30.91%	EPS Surprise	10.82%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	428.80K	Price	1.07
SMA20	2.75%	SMA50	3.81%	SMA200	9.64%	Trades		Volume	354,500	Change	-6.95%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-21-22	Initiated	Chardan Capital Markets	Buy	$7
Jan-10-22	Initiated	H.C. Wainwright	Buy	$36
Nov-16-21	Initiated	Raymond James	Outperform	$31
Nov-16-21	Initiated	Morgan Stanley	Overweight	$32
Nov-16-21	Initiated	Guggenheim	Buy	$40
Nov-16-21	Initiated	Cowen	Outperform

Dec-19-24 07:30AM	Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI (GlobeNewswire) +8.25%
Dec-16-24 07:30AM	Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer (GlobeNewswire)
Dec-09-24 09:55AM	After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright (Zacks)
Dec-03-24 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-24 09:15AM	Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors (GlobeNewswire) -19.38%
09:05AM	Loading…
09:05AM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 09:01AM	Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire) +38.38%
Oct-04-24 09:05AM	Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire) +7.51%
Oct-02-24 04:15PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-28-24 04:01PM	Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire) -10.98%
Aug-08-24 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-13-24 04:05PM	Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors (GlobeNewswire)
May-29-24 06:05AM	Gilead and Cartography enter deal to develop cancer therapies (Pharmaceutical Technology)
May-14-24 01:54PM	XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results (GlobeNewswire)
09:14AM	Loading…
Apr-16-24 09:14AM	Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why (Zacks)
Apr-01-24 10:53PM	XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +41.67%
04:05PM	Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-28-24 11:10AM	Why Is Xilio Therapeutics (XLO) Stock up 168% Today? (InvestorPlace) +69.01%
07:05AM	Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing (GlobeNewswire)
07:00AM	Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program (GlobeNewswire)
06:45AM	Gilead bets on Xilio cancer drug as biotech restructures (BioPharma Dive)
Feb-28-24 04:01PM	Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +5.60% +7.42%
Jan-31-24 04:01PM	Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-08-24 07:30AM	Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies (GlobeNewswire)
Dec-07-23 07:30AM	Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data (GlobeNewswire)
Nov-09-23 04:01PM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results (GlobeNewswire) -13.04% -10.63%
Nov-03-23 12:00PM	Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors (GlobeNewswire)
Oct-31-23 09:15AM	Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting (GlobeNewswire)
Sep-27-23 05:02PM	Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire)
08:30AM	Loading…
Sep-05-23 08:30AM	Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer (GlobeNewswire)
07:30AM	Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-18-23 04:27AM	Q2 2023 Xilio Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 04:05PM	Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer (GlobeNewswire)
May-25-23 05:01PM	Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors (GlobeNewswire)
May-09-23 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-03-23 04:05PM	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.09%
Mar-02-23 04:05PM	Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -7.37%
Feb-27-23 07:30AM	Xilio Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.72%
Feb-16-23 07:30AM	Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-02-23 07:30AM	Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day (GlobeNewswire)
Jan-26-23 05:30AM	Institutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the most (Simply Wall St.)
Jan-25-23 09:45AM	These 2 Strong Buy Penny Stocks Are on Track for Massive Gains, Say Analysts (TipRanks) +36.92%
Nov-23-22 07:30AM	Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12 (GlobeNewswire) +7.94%
Nov-09-22 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-04-22 07:30AM	Xilio Therapeutics to Present at Cowen 6th Annual IO Next Summit (GlobeNewswire)
Sep-22-22 04:05PM	Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference (GlobeNewswire)
Sep-15-22 04:05PM	Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors (GlobeNewswire) +15.38%
Sep-06-22 04:05PM	Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire) +8.21%
Aug-11-22 09:41AM	Is Xilio Therapeutics (NASDAQ:XLO) In A Good Position To Invest In Growth? (Simply Wall St.)
Aug-09-22 07:30AM	Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results (GlobeNewswire) -26.22%
Jun-16-22 07:30AM	Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President (GlobeNewswire)
May-18-22 07:30AM	Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -9.56%
May-17-22 07:30AM	Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer (GlobeNewswire) -5.18%
May-12-22 07:30AM	Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results (GlobeNewswire)
Apr-07-22 06:30AM	Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-01-22 06:30AM	Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) -7.56%
Feb-28-22 06:30AM	Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference (GlobeNewswire) -10.42%
Feb-07-22 05:38PM	RiverVest Venture Management LLC Buys Xilio Therapeutics Inc (GuruFocus.com)
Feb-03-22 06:30AM	Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day (GlobeNewswire)
Jan-25-22 10:27AM	Are Institutions Heavily Invested In Xilio Therapeutics, Inc.'s (NASDAQ:XLO) Shares? (Simply Wall St.)
Jan-20-22 07:30AM	Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors (GlobeNewswire) +9.79%
Jan-06-22 07:30AM	Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors (GlobeNewswire)
Dec-02-21 07:30AM	Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results (GlobeNewswire) -12.46%
Nov-12-21 07:00AM	Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting (GlobeNewswire) -6.69%
Oct-27-21 07:45AM	4 Stocks Insiders Are Buying (Benzinga)
Oct-26-21 04:05PM	Xilio Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire)

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GILEAD SCIENCES, INC.	10% Owner	Dec 18 '24	Buy	1.04	1,759,978	1,830,377	9,105,451	Dec 19 04:19 PM
GILEAD SCIENCES, INC.	10% Owner	Apr 02 '24	Buy	0.76	485,250	368,790	7,345,473	Apr 03 06:50 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 08 '24	Sale	0.64	733	469	2,019,563	Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 08 '24	Sale	0.64	267	171	734,546	Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.	10% Owner	Jan 11 '24	Sale	0.87	1,566	1,362	2,021,836	Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.	10% Owner	Jan 12 '24	Sale	0.83	1,540	1,278	2,020,296	Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.	10% Owner	Jan 11 '24	Sale	0.87	569	495	735,373	Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.	10% Owner	Jan 12 '24	Sale	0.83	560	465	734,813	Jan 16 06:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XLO

Xilio Therapeutics Inc

Upgrade your FINVIZ experience